Navigation Links
Simcere Pharmaceutical Group to Announce Third Quarter 2013 Financial Results on Thursday, November 14, 2013
Date:11/1/2013

NANJING, China, Nov. 1, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2013 on Thursday, November 14, 2013, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Thursday, November 14, at 9 p.m. Beijing / Hong Kong time).

To access the conference call, please dial:International toll:+65.6723.9381United States toll-free:+1.866.519.4004United States toll:+1.845.675.0437China Domestic toll:800.819.0121 China Domestic mobile toll:400.620.8038 Hong Kong toll:+852.2475.0994Please ask to be connected to Q3 2013 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 94745140

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:+1.855.452.5696United States toll:+1.646.254.3697The passcode for replay participants is 94745140. The telephone replay also will be archived on the "Investor Relations" section of the company's website for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts: Email: ir@simcere.comIn Nanjing:In the United States:Vivien LiangCindy ZhengSimcere Pharmaceutical GroupBrunswick GroupTel: 86-25-8556-6666*8857Tel: 1-212-333-3810In Beijing: Yue Yu Brunswick Group Tel: 86-10-5960-8600
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Enters Into Definitive Merger Agreement for Going Private Transaction
2. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2013 Results
3. Simcere Pharmaceutical Group to Announce Second Quarter 2013 Financial Results on Tuesday, August 13, 2013
4. Simcere Pharmaceutical Group Announces Sale of Equity Interest in Boda
5. Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China
6. Simcere Pharmaceutical Group Announces Resignation of Chief Scientific Officer
7. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2013 Results
8. Simcere Pharmaceutical Group Filed 2012 Annual Report on Form 20-F
9. Simcere Pharmaceutical Group to Announce First Quarter 2013 Financial Results on Thursday, May 9, 2013
10. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Financial Advisor
11. Simcere Pharmaceutical Group Announces Issuance of GMP Certificate to Simcere Vaxtec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  True Health, ... has amplified its effort during National Breast Cancer ... hereditary cancer risks. ... Clinical Oncology calculated that more than 10 million ... inherited mutations in BRCA1 or BRCA2 and have not ...
(Date:10/7/2017)... IRVING, Texas , Oct. 6, 2017   ... industry with more than $100 billion in purchasing power, ... industry news and information. The Newsroom is ... chain and industry trends, infographics, expert bios, news releases, ... Besides having access to a wealth of resources at ...
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... of the most popular and least understood books in the Holy Scriptures, Revelation. The ... that have baffled scholars for centuries. Many have tossed it off as mere rubbish, ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... Fla. (PRWEB) , ... October 12, 2017 , ... IsoComforter, ... therapy products, announced today the introduction of an innovative new design of the shoulder ... pad so you get maximum comfort while controlling your pain while using cold therapy. ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
Breaking Medicine News(10 mins):